Press Release Details

BASKING RIDGE, N.J., Feb. 1, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading development and manufacturing services provider (PCT), announces today that the Company’s leadership and experts will present at the following upcoming February conferences:

BIO CEO & Investor Conference

• Date and Time: Monday, February 13, 2017, 1:30 PM ET
• Website: https://www.bio.org/events/bio-ceo-investor-conference
• Venue: The Waldorf Astoria, New York, New York
• Topic: Company Presentation
• Presenter: David J. Mazzo, PhD, Chief Executive Officer, Caladrius
• Webcast: https://www.caladrius.com//events

Molecular Med Tri-Con 2017

• Date and Time: Monday, February 20, 2017, 8:00 AM PT
• Website: http://www.triconference.com
• Venue: Moscone North Convention Center, San Francisco, CA
• Panel: From Idea to Industry: A History of CAR T-Cells to Where We Are Today, and the Challenges of Commercialization
• Panelist: Cenk Sumen, PhD, Senior Manager, Business Development, PCT

AABB Session

• Date and Time: Thursday, February 23, 2017, 2:00 PM ET
• Website: http://www.aabb.org/development/elearning/Pages/113.aspx
• Webinar: Apheresis Optimization in Gene and Immunotherapy Development in Non-Mobilized Patients and Donors
• Panelist: Sanjin Zvonic, PhD, Senior Director, Business Leader, PCT

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The company’s subsidiary, PCT, is a leading development and manufacturing partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. PCT provides a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. For more information on Caladrius please visit www.caladrius.com and for more information on PCT please visit www.pctcaladrius.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

Source: Caladrius Biosciences, Inc.